Proautophagic drugs: A novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas

Oncologist

Volumn 12, Issue 12, 2007, Pages 1395-1403

  Lefranc, Florence ^a,b   Facchini, Vincenzo ^c   Kiss, Robert ^b  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c Unibioscreen SA   (Belgium)

Author keywords

Apoptosis; Autophagy; Glioblastoma; Melanoma; Metastatic cancer; Temozolomide

Indexed keywords

AP 23573; ARSENIC TRIOXIDE; BUTYRIC ACID; CASPASE; CASPASE 2; CASPASE 7; CASPASE 9; CERAMIDE; CYTOTOXIC AGENT; DOPAMINE; DOXORUBICIN; ENDOSTATIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NEODYMIUM OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN P53; RAPAMYCIN; RESVERATROL; SAPONIN DERIVATIVE; SEOCALCITOL; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CELL SURVIVAL; CELL VACUOLE; CYTOPLASM; DEGRADATION; DRUG TARGETING; ENDOPLASMIC RETICULUM; GLIOBLASTOMA; GOLGI COMPLEX; HUMAN; MITOSIS; NONHUMAN; POLYSOME; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE;

EID: 38049027838     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-12-1395     Document Type: Review

References (84)

1. Viktorsson K, Lewensohn R, Zhivotovsky B. Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res 2005;94:143-196.
2. Ricci MS, Zong WX. Chemotherapeutic approaches for targeting cell death pathways. The Oncologist 2006;11:342-357.
3. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603.
4. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-885.
5. McCarthy N. Therapy: Inhibiting the inhibitors. Nat Rev Cancer 2007;7:5.
6. Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-4745.
7. Tolcher AW, Chi K, Kuhn J et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005;11:3854-3861.
8. Rowinsky EK. Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005;23:9394-9407.
9. Duiker EW, Mom CH, de Jong S et al. The clinical trail of TRAIL. Eur J Cancer 2006;42:2233-2240.
10. Marini P. Drug evaluation: Lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2. Curr Opin Mol Ther 2006;8:539-546.
11. Sun H, Nikolovska-Coleska Z, Lu J et al. Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. J Med Chem 2006;49:7916-7920.
12. McCubrey JA, Steelman LS, Abrams SL et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006;46:249-279.
13. Clark AS, West K, Streicher S et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab or tamoxifen in breast cancer cells. Mol Cancer Ther 2002;1:707-717.
14. Liang K, Lu Y, Li X et al. Differential roles of phosphoinositide- dependent protein kinase-1 and Akt1 expression and phosphorylation in breast cancer cell resistance to paclitaxel, doxorubicin, and gemcitabine. Mol Pharmacol 2006;70:1045-1052.
15. Hu L, Hofmann J, Lu Y et al. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002;62:1087-1092.
16. O'Rourke DM. Targeted molecular therapy in glial tumors. Neurosurgery 2004;54:N9.
17. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: Special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23:2411-2422.
18. Joy AM, Beaudry CE, Tran NL et al. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 2003;116:4409-4417.
19. Shingu T, Yamada K, Hara N et al. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells. Cancer Res 2003;63:4044-4047.
20. Cheung HW, Ling MT, Tsao SW et al. Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 2004;25:881-887.
21. McCormick F. Cancer: Survival pathways meet their end. Nature 2004;428:267-269.
22. Bjornsti MA, Houghton P. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 2004;4:335-348.
23. Reardon DA, Quinn JA, Vredenburgh JJ et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006;12:860-868.
24. Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003;22:3152-3161.
25. Malhi H, Gores GJ. TRAIL resistance results in cancer progression: A TRAIL to perdition? Oncogene 2006;25:7333-7335.
26. Aggarwal BB. Nuclear factor-kappaB: The enemy within. Cancer Cell 2004;6:203-208.
27. Reggiori F, Klionsky DJ. Autophagy in the eukaryotic cell. Eukaryot Cell 2002;1:11-21.
28. De Duve C, Wattiaux R. Functions of lysosomes. Annu Rev Physiol 1966;28:435-492.
29. Schweichel JU, Merker HJ. The morphology of various types of cell death in prenatal tissues. Teratology 1973;7:253-266.
30. Lum JJ, Bauer DE, Kong M et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005;120:237-248.
31. Kanzawa T, Germano IM, Komata T et al. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004;11:448-457.
32. Kondo Y, Kanzawa T, Sawaya R et al. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005;5:726-734.
33. Shintani T, Klionsky DJ. Autophagy in health and disease: A double-edged sword. Science 2004;306:990-995.
34. Lefranc F, Kiss R. Autophagy, the Trojan horse to combat glioblastomas. Neurosurg Focus 2006;20:E7.
35. Inbal B, Bialik S, Sabanay I et al. DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death. J Cell Biol 2002;157:455-468.
36. Lockshin RA, Zakeri Z. Apoptosis, autophagy and more. Int J Biochem Cell Biol 2004;36:2405-2419.
37. Pattingre S, Levine B. Bcl-2 inhibition of autophagy: A new route to cancer? Cancer Res 2006;66:2885-2888.
38. Feng Z, Zhang H, Levine AJ et al. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 2005;102:8204-8209.
39. Jin S. p53, autophagy and tumor suppression. Autophagy 2005;1:171-173.
40. Crighton D, Wilkinson S, O'Prey J et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006;126:121-134.
41. Gunn JM, Clark MG, Knowles SE et al. Reduced rates of proteolysis in transformed cells. Nature 1977;266:58-60.
42. Otsuka H, Moskowitz M. Differences in the rates of protein degradation in untransformed and transformed cell lines. Exp Cell Res 1978;112:127-135.
43. Liang XH, Jackson S, Seaman M et al. Induction of autophagy and inhibition of tumorigenesis by beclin1. Nature 1999;402:672-676.
44. Aita VM, Liang XH, Murty VV et al. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 1999;59:59-65.
45. Miracco C, Cosci E, Oliveri G et al. Protein and mRNA expression of autophagy gene Beclin 1 in human brain tumours. Int J Oncol 2007;30:429-436.
46. Chen T, Sahin A, Aldaz CM. Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: Refining a putative tumor suppressor gene region. Cancer Res 1996;56:5605-5609.
47. Elo JP, Harkonen P, Kyllonen AP et al. Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res 1997;57:3356-3359.
48. Suzuki S, Moore DH 2nd, Ginzinger DG et al. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 2000;60:5382-5385.
49. Miyakis S, Liloglou T, Kearney S et al. Absence of mutations in the VHL gene but frequent loss of heterozygosity at 3p25-26 in non-small cell lung carcinomas. Lung Cancer 2003;39:273-277.
50. Ogier-Denis E, Codogno P. Autophagy: A barrier or an adaptive response to cancer. Biochim Biophys Acta 2003;1603:113-128.
51. Gozuacik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004;23:2891-2906.
52. Eshleman JS, Carlson BL, Mladek AC et al. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 2002;62:7291-7297.
53. Paglin S, Hollister T, Delohery T et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 2001;61:439-444.
54. Kanzawa T, Zhang L, Xiao L et al. Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene 2005;24:980-991.
55. Daido S, Kanzawa T, YamamotoAet al. Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells. Cancer Res 2004;64:4286-4293.
56. Gomez-Santos C, Ferrer I, Santidrian AF et al. Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cells. J Neurosci Res 2003;73:341-350.
57. Chau YP, Lin SY, Chen JH et al. Endostatin induces autophagic cell death in EAhy926 human endothelial cells. Histol Histopathol 2003;18:715-726.
58. Shao Y, Gao Z, Marks PA et al. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2004;101:18030-18035.
59. Chen Y, Yang L, Feng C et al. Nano neodymium oxide induces massive vacuolization and autophagic cell death in non-small cell lung cancer NCI-H460 cells. Biochem Biophys Res Commun 2005;337:52-60.
60. Hoyer-Hansen M, Bastholm L, Mathiasen IS et al. Vitamin D analog EB1089 triggers dramatic lysosomal changes and beclin 1-mediated autophagic cell death. Cell Death Differ 2005;12:1297-1309.
61. Ellington AA, Berhow M, Singletary KW. Induction of macroautophagy in human colon cancer cells by soybean B-group triterpenoid saponins. Carcinogenesis 2005;26:159-167.
62. Opipari AW Jr, Tan L, Boitano AE et al. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 2004;64:696-703.
63. Iwamaru A, Kondo Y, Iwado E et al. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 2007;26:1840-1851.
64. Stupp R, Mason WP, van den Bent MJ et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
65. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: Rationale and potential role of targeted agents. The Oncologist 2006;11:152-164.
66. Kanzawa T, Bedwell J, Kondo Y et al. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 2003;99:1047-1052.
67. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
68. Roos WP, Batista LF, Naumann SC et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007;26:186-197.
69. Maiuri MC, Zalckvar E, Kimchi A et al. Self-eating and self-killing: Crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007;8:741-752.
70. Schilsky RL. End points in cancer clinical trials and the drug approval process. Clin Cancer Res 2002;8:935-938.
71. Nozawa H, Watanabe T, Nagawa H. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett 2007;251:105-113.
72. Kim R, Emi M, TanabeKet al. Role of the unfolded protein response in cell death. Apoptosis 2006;11:5-13.
73. Hori O, Ichinoda F, Yamaguchi A et al. Role of Herp in the endoplasmic reticulum stress response. Genes Cell 2004;9:457-469.
74. Kurisu J, Honma A, Miyajima H et al. MDG1/ERdj4, an ER-resident DnaJ family member, suppresses cell death induced by ER stress. Genes Cells 2003;8:189-202.
75. Zhao L, Ackerman SL. Endoplasmic reticulum stress in health and disease. Curr Opin Cell Biol 2006;18:444-452.
76. Fu Y, Lee AS. Glucose regulated proteins in cancer progression, drug resistance and immunotherapy. Cancer Biol Ther 2006;5:741-744.
77. Ranganathan AC, Zhang L, Adam AP et al. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res 2006;66:1702-1711.
78. Altieri DC. Coupling apoptosis resistance to the cellular stress response: The IAP-Hsp90 connection in cancer. Cell Cycle 2004;3:255-256.
79. Fels DR, Koumenis C. The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol Ther 2006;5:723-728.
80. Park HR, Tomida A, Sato S et al. Effect on tumor cells of blocking survival response to glucose deprivation. J Natl Cancer Inst 2004;96:1300-1310.
81. Meli M, Pennati M, Curto M et al. Small-molecule targeting of heat shock protein 90 chaperone function: Rational identification of a new anticancer lead. J Med Chem 2006;49:7721-7730.
82. Vastag B. HSP-90 inhibitors promise to complement cancer therapies. Nat Biotechnol 2006;24:1307.
83. Sharp S, Workman P. Inhibitors of the HSP90 molecular chaperone: Current status. Adv Cancer Res 2006;95:323-348.
84. Schmitt E, Maingret L, Puig PE et al. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res 2006;66:4191-4197.